AlloCure Pockets $25M for Acute Kidney Injury Stem Cell Therapy Genetic Engineering News The company is developing AC607, an allogeneic mesenchymal stem cell therapy, for acute kidney injury (AKI) and believes that the funding will allow it to complete Phase II trials. “A treatment for AKI is an important unmet medical need, recognized by ... AlloCure Raises $25 Million Series B Venture Financing Lundbeckfond leads $25M B round for AlloCure's Phase II stem cell study AlloCure raises $25M round for kidney disease trial |
